King's College London

Research portal

Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with selenoprotein N-related myopathies

Research output: Contribution to journalArticle

Christoph Bachmann, Faiza Noreen, Nicol C. Voermans, Primo L. Schär, John Vissing, Johanna M. Fock, Saskia Bulk, Benno Kusters, Steven A. Moore, Alan H. Beggs, Katherine D. Mathews, Megan Meyer, Casie A. Genetti, Giovanni Meola, Rosanna Cardani, Emma Mathews, Heinz Jungbluth, Francesco Muntoni, Francesco Zorzato, Susan Treves

Original languageEnglish
Pages (from-to)962-974
Number of pages13
JournalHuman Mutation
Volume40
Issue number7
Early online date1 Apr 2019
DOIs
Publication statusPublished - 1 Jul 2019

King's Authors

Abstract

Congenital myopathies are early onset, slowly progressive neuromuscular disorders of variable severity. They are genetically and phenotypically heterogeneous and caused by pathogenic variants in several genes. Multi-minicore Disease, one of the more common congenital myopathies, is frequently caused by recessive variants in either SELENON, encoding the endoplasmic reticulum glycoprotein selenoprotein N or RYR1, encoding a protein involved in calcium homeostasis and excitation–contraction coupling. The mechanism by which recessive SELENON variants cause Multiminicore disease (MmD) is unclear. Here, we extensively investigated muscle physiological, biochemical and epigenetic modifications, including DNA methylation, histone modification, and noncoding RNA expression, to understand the pathomechanism of MmD. We identified biochemical changes that are common in patients harboring recessive RYR1 and SELENON variants, including depletion of transcripts encoding proteins involved in skeletal muscle calcium homeostasis, increased levels of Class II histone deacetylases (HDACs) and DNA methyltransferases. CpG methylation analysis of genomic DNA of patients with RYR1 and SELENON variants identified >3,500 common aberrantly methylated genes, many of which are involved in calcium signaling. These results provide the proof of concept for the potential use of drugs targeting HDACs and DNA methyltransferases to treat patients with specific forms of congenital myopathies.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454